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Abstract
Objective: The aim of this study was to examine Factor V G1691A (Leiden) (FVL) and prothrombin 
G20210A (PT) gene mutation status, and their relationship with thrombosis in patients with chronic 
myeloproliferative disorders (CMPDs).
Materials and Methods: The study included 160 patients with a CMPD that were regularly followed-up 
between 1993 and 2009. FVL and PT mutation status was established based on blood samples ana-
lyzed via PCR using specific primers.
Results: The frequency of FVL and PT mutation was 12.5% and 4.4%, respectively. In total, 27 epi-
sodes of thrombosis occurred in 24 (15%) of the patients, and there wasn’t an association between the 
observed thrombotic events, and FVL or PT mutations. Hepatic vein thrombosis was noted in 3 
patients that had FVL mutation, of which 1 also had PT mutation.
Conclusion: We did not observe a relationship between thrombosis, and FVL or PT mutations in 
CMPD patients; however, 3 of the patients that had hepatic vein thrombosis also had FVL mutation. 
Larger studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombo-
sis need be investigated for FVL and PT mutation. (Turk J Hematol 2011; 28: 306-11)
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Özet
Amaç: Bu çalışmanın amacı, kronik myeloproliferatif hastalık (KMPH) tanılı hastalarda Factor V 
G1691A (Leiden) (FVL) ve protrombin (PT) gen mutasyonu durumunu ve bunların trombotik komp-
likasyonlarla ilişkisini değerlendirmektir.
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Arterial  and  venous  thrombosis  are  common 
causes of morbidity and mortality in patients with 
chronic  myeloproliferative  disorders  (CMPDs). 
Generally,  thrombotic  events  are  more  frequently 
reported  than  bleeding  complications  in  patients 
with  essential  thrombocythemia  (ET)  and  polycy-
themia vera (PV) at the time of diagnosis and during 
follow-up [1]. The frequency of thrombotic events 
in patients with idiopathic myelofibrosis (IMF) was 
reported to be 7.2%-11.6% [2,3]. 
Factor V G1691A (Leiden) (FVL) and prothrom-
bin 20210A (PT) gene mutations are the most com-
mon  genetic  anomalies  factors  in  patients  with 
venous thromboembolism. The frequency of FVL 
ranges from 1.4% in Italy to 7% in Greece [4]. In the 
general  Caucasian  population  the  prevalence  of 
the  PT  20210A  allele  is  2%  showing  difference 
according to geographic variation approximately 2%, 
with some geographic variation [5]. The prevalence 
of FVL and PT mutation in Turkey was reported to be 
7.4%-10.8% and 2.6%, respectively [6-10], which dif-
fers  from  the  reported  incidence  of  FVL  and  PT 
mutation in patients with ET and PV [11-13]. To the 
best of our knowledge the frequency of FVL and PT 
mutation in patients with IMF has not been report-
ed. Furthermore, the relationship between throm-
bophilic factors such as FVL and protrombine muta-
tions thrombophilic factors and the occurrence of 
thrombosis  in  patients  entering  this  study  these 
patients remains unclear. As such, the present study 
aimed to determine the FVL and PT mutation sta-
tus, and the relationship between these mutations 
and thrombosis in patients with CMPDs.
Materials and Methods
The study included 160 CMPD patients that were 
regularly follow-up at our hematology department 
between  January  1993  and  September  2009. 
Diagnosis  of  CMPDs  was  based  on  the  criteria 
accepted  at  the  time  the  patients  presented 
(PSVSG14).  All  patients  were  informed  about  the 
study and provided written informed consent, and 
the Ege University Local Ethics Committee approved 
the study protocol.
Blood samples (3 mL of peripheral blood) were 
collected  into  tubes  containing  EDTA)  between 
February  2008  and  September  2009.  Patient  data 
were  collected  at  the  time  of  sample  collection 
based  on  the  patient  files,  and  included  date  of 
diagnosis, occurrence of arterial and venous throm-
bosis,  symptoms,  and  complete  blood  count  and 
other laboratory measurements at the time of diag-
nosis.
We  used  the  blood  samples  to  identify  FVL 
G1691A and PT 20210A gene mutations. Genomic 
DNA  was  extracted  from  peripheral  leukocytes 
using the High Pure PCR Template Preparation Kit 
(Roche Applied Science). In brief, 200 μL of DNA 
binding buffer (6 M guanidine-HCl, 10 mM urea, 10 
mM Tris-HCl, and 20% Triton X-100 [pH 4.4]) and 40 
μL of proteinase K were added to 200 μL of EDTA-
containing blood. The mixture containing protein-
ase K was incubated for 10 min at 72°C, and then 
100  μL  of  isopropanol  was  added  to  the  mixture 
samples, which were placed in filter tubes contain-
ing glass fiber (in order to bind DNA) and centri-
fuged at 8000 rpm. The DNA that bound to the filter 
tubes was washed twice with buffer (20 mM NaCl 
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Yöntemler ve Gereçler: 1993-2009 yılları arasında düzenli olarak takip edilen 160 KMPH hastası 
çalışmaya alındı. FVL ve PT mutasyon durumunu saptamak için kan örnekleri toplandı ve spesifik 
primerler kullanılarak PCR ile değerlendirildi. 
Bulgular: FVL ve PT mutasyonu sıklığı sırasıyla %12.5 ve %4.4 olarak bulundu. 24 hastada (%15) 
toplam 27 tromboz atağı saptandı ve bu mutasyonlarla tromboz gelişimi arasında herhangi bir ilişki 
gösterilemedi. FVL mutasyonu olan hastaların 3’ünde hepatik ven trombozu saptandı ve 3 hastanın 
1’inde PT mutasyonu da vardı. 
Sonuç: TKMPH’lı hastalarda FVL ve PT mutasyonu ile tromboz arasında herhangi bir ilişki gösterile-
medi. Ancak, biz FVL mutasyonu olan hepatik ven trombozlu 3 KMPH hastası saptadık. Hepatik ven 
trombozlu tüm KMPH hastalarında FVL ve PT mutasyonu bakılmasına gerek olup olmadığını sapta-
mak için büyük çalışmalara ihtiyaç olduğu gözükmektedir. (Turk J Hematol 2011; 28: 306-11)
Anahtar kelimeler: Kronik myeloproliferatif hastalıklar, Faktör V Leiden mutasyonu, protrombin gen 
mutasyonu, tromboz
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(10 mM Tris [pH 8.5]) was then added to the DNA-
bound filter tubes, which were then centrifuged at 
8000 rpm to collect DNA. DNA solutions obtained 
with this procedure were directly available for FVL 
and  PT  mutation  analysis,  which  was  performed 
according to the manufacturer’s instructions. 
The presence of FVL G1691A and PT G20210A 
mutation  was  analyzed  using  commercially  avail-
able  Light  Cycler  FVL  and  PT  mutation  detection 
kits (Roche Applied Science). Wild type and mutat-
ed alleles were identified using the specific melting 
temperature (Tm) of the resulting amplicons. Tm 
values for FVL were 65°C for the wild type allele and 
57°C for the G1691A allele, and for PT 60°C for the 
wild type allele and 49°C for the G20210A allele.
Statistical analysis
Statistical  analysis  of  the  data  was  performed 
with  using  SPSS  v.12.0  for  Windows  (SPSS  Inc, 
Chicago, III). Fisher’s exact test was used to deter-
mine  the  significance  of  the  difference  between 
categorical variables (arterial and venous thrombo-
sis, FVL and PT mutation, diagnostic subgroups). P 
values <0.05 were accepted as statistically signifi-
cant.
Results 
Among the 160 CMPD patients, 88 (55%) had ET, 
48 (30%) had PV, 15 (9.3%) had IMF, and 9 (5.7%) 
had  an  unclassified  CMPD.  Median  age  of  the 
patients (88 males and 77 females) was 59 years 
(range: 21-88 years). Patient characteristics are pre-
sented in Table 1. 
As at the time of presentation the patients’ symp-
toms were quite varied, symptoms were classified 
based  on  systems.  The  patients’  symptoms  are 
shown in Table 2.
In total, 27 episodes of thrombosis occurred in 24 
(15%) of the 160 patients, and included 12 arterial 
and 15 venous episodes. Hepatic vein thrombosis 
was noted in 3 patients with FVL mutation, of which 
and 1 also had PT mutation. In all, 7 patients had 
portal vein thrombosis, none of which had FVL or 
PT mutation. The frequency of arterial and venous 
thrombotic  events  did  not  differ  between  patient 
diagnostic subgroups (p>0.05). Whereas 16 (18.2%) 
thrombotic events were documented in 88 patients 
with ET, 7 (14.5%) thrombotic events were recorded 
in 48 patients with PV. In all, 2 thrombotic events 
(13.3%) occurred in 1 of the 15 patients with IMF, 
which were not associated with any thrombophilic 
factors. FVL and PT gene mutations were noted in 
20 (12.5%) and 7 (4.4%) of the 160 CMPD patients, 
Soyer et al.
Thrombosis in CMPD Turk J Hematol 2011; 28: 306-11 308
Table 1. Patient Characteristics
Characteristics   Total   ET   PV   IMF   Unclassified CMPD 
n   160  88    48  15  9
Age (years)  59 (21-88)*  57 (21-88)*  59.5 (24-82)*  60 (32-80)*  62 (36-75)*
Male  83  49  29  9  6
Female   77  39  19  6  3
Months since diagnosis  31.5 (5-282)*  27 (5-160)*  42.5 (5-282)*  25 (5-147)*  24 (15-136)*
Hematocrit (%)  44 (20-70)*  40.05 (26-51.7)*  57.55 (34.1-70)*  36 (20-52.9)*  47.8 (38-57)*
Platelet count (×109/L)   758 (88-2819)*  963 (115-2819)*  473.5 (95-1380)*  356 (88-1250)*  564 (138- 1436)*
White blood cell count (×109/L)  11.4 (3.15-73)*  10.2 (4.87-35)*  13 (7.13-40.2)*  13.2 (3.15-73)*  14.8 (4.82-44.4)*
ESR (mm/h)  6 (2-61)*  9 (2-61)*  5.5 (2-22)*  16 (2-46)*  2.5 (2-7)*
LDH (/UL)  419 (131-2841)*  400 (131-991)*  407.5 (134- 2201)*  1026 (638-2841)*  440 (244-1180)*
*Median (range)
Table 2. Frequency of Symptoms
Symptoms   n  %
Thrombocytosis based on routine CBC  64  40
Neurologic symptoms  24  15
Polycythemia based on routine CBC   18  11.3
Gastrointestinal symptoms  16  10
Hematologic symptoms  9  5.6
Systemic symptoms  8  5
Others   8  5
Ruddy cyanosis  5  3.1
Cardiovascular and pulmonary symptoms  3  1.9
Pruritus   3  1.9
Visual symptoms  2  1.2
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erozygous  (Table  3).  In  total,  5  (21%)  of  the  24 
patients  with  thrombosis  had  FVL  mutation,  of 
which 1 also had PT gene mutation. There wasn’t 
an association between thrombosis, and FVL or PT 
mutation carriership (p>0.05).
The clinical characteristics of the patients (age, 
erythrocyte  sedimentation  rate  [ESR],  leukocyte 
count, hematocrit, platelet count, and lactate dehy-
drogenize [LDH]) with and without FVL mutation 
did not differ (p>0.05), nor did those of the patients 
with  and  without  PT  gene  mutation  (p>0.05). 
Arterial  and  venous  thrombotic  events  were  not 
associated  with  the  presence  of  FVL  or  PT  gene 
mutation (p>0.05). 
Discussion
Thrombotic events during the clinical course of 
CMPDs cause morbidity and mortality. Prevention of 
these events is among the primary goals of the treat-
ment  of  CMPDs.  In  addition,  hereditary  thrombo-
philic  factors  are  the  most  important  cause  of 
venous thrombosis. It remains unclear if there is a 
relationship between these factors and thrombotic 
events in CMPD. The present study examined the 
frequency of FVL and PT mutation in CMPD patients, 
as  well  as  the  relationship  between  FVL  and  PT 
mutation,  and  arterial  and  venous  thrombotic 
events.
The  frequency  of  thrombotic  events  in  the 
patients with ET and PV (18.2% and 14.5%, respec-
tively) was similar to that previously reported (11%-
29.4% and 13%-38.6%, respectively) [1,15]. In all, 2 
(13.3%) thrombotic events occurred in 1 of the 15 
patients with IMF in the present study. A retrospec-
tive study reported that 11 of 26 patients with IMF 
had  arterial  or  venous  thrombosis  [13,14,16]. 
Cervantes et al. reported that 31 (20%) thrombotic 
events occurred in 18 of 155 IMF patients [2]. Barbui 
et al. assessed the frequency of major cardiovascu-
lar events in 707 patients with IMF; fatal and non-
fatal thrombosis occurred in 51 (7.2%) of the patients 
[3], although among the IMF patients in the present 
study  the  rate  was  (6.6%)  slightly  lower.  It  was 
reported that arterial events are very common at the 
time  of  diagnosis  in  PV  and  ET  patients,  but  we 
observed similar frequencies of arterial and venous 
events  in  ET  (8%  and  10.2%)  and  PV  (8.3%  and 
6.2%) patients [17-20]. 
In the present study the frequency of FVL muta-
tion was 12.5%, which is (7.4%-10.8) slightly higher 
than previously reported [6,7,10]. The frequency of 
PT mutation was 4.4% in the present study-2-fold 
greater than in the general population [5,8,9]. While 
the  frequency  of  these  mutations  in  the  present 
study was higher than previously reported, a rela-
tionship between thrombosis, and these mutations 
in patients with ET, PV, and IMF was not observed. A 
large retrospective study reported that the frequen-
cy of FVL mutation in PV and ET patients was simi-
lar to that in the general population and that the 
mutation  was  strongly  associated  with  venous 
thrombotic events prior to and at the time of diagno-
sis  and  relapse  [11].  Another  study  reported  that 
there was an increase in the risk of thromboem-
bolic events in patients with ET and PV due to PT 
mutation [21]. In contrast, some studies reported 
that there wasn’t a significant association between 
thrombosis and hereditary thrombophilic factors in 
CMPD patients [12,13]. Although leukocytosis is a 
risk factor for thrombosis in patients with PV and ET 
[19,20,22,23], the role of hereditary thrombophilic 
factors for etiology of thrombosis in those disorders 
remains unclear.
All patients in the present study with hepatic vein 
thrombosis had FVL mutation carriership, of which 
1 also had PT mutation; however, none of patients 
with  portal  vein  thrombosis  had  a  thrombophilic 
mutation. FVL and PT mutations were observed in 
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Table 3. Frequency of Thrombotic Events and Gene Mutations
  Factor V   Prothrombin  Total  Venous  Arterial 
  Leiden  20210A  thrombotic  thrombotic  thrombotic 
      events  events  events 
CMPD Patients (n=160)   20 (12.5%)  7 (4.4%)  27 (16.9%)  15 (9.4%)  12 (7.5%)
ET (n=88)  13 (14.7%)  3 (3.4%)  16 (18.2%)  9 (10.2%)  7 (7.9%)
PV (n=48)  4 (8.3%)  3 (6.25%)  7 (14.5%)  3 (6.25%)  4 (8.3%)
IMF (n=15)  2 (13.3%)  1 (6.6%)  2 (13.3%)  2 (13.3%)  0 (0%)
Unclassified CMPD (n=9)  1 (11.1%)  0 (0%)  2 (22.2%)  1 (11.1%)  1 (11.1%)
TJH-ARALIK-2011-4-crossref.indd   61 02.12.2011   10:1425.6%-26.4%  and  0%-4.7%  of  patients  with  Budd 
Chiari syndrome, and in 6.06%-7.6% and 0%-3.2% of 
patients  with  portal  vein  thrombosis,  respectively 
[24,25].  Furthermore,  the  prevalence  of  a  latent 
CMPD in patients with hepatic or portal vein throm-
bosis was estimated to range between 40% and 60% 
[26,27]. 
In conclusion, even though there wasn’t a rela-
tionship between thrombosis, and FVL or PT muta-
tion in the present study’s patients with ET, PV, and 
PMF, 3 CMPD patients with hepatic vein thrombosis 
had FVL mutation. Additional large-scale studies are 
needed  to  more  clearly  determine  if  all  CMPD 
patients  with  hepatic  vein  thrombosis  should  be 
investigated for FVL and PT mutation.
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